Insight Wealth Strategies LLC grew its position in Zoetis Inc (NYSE:ZTS) by 31.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 15,541 shares of the company’s stock after purchasing an additional 3,699 shares during the period. Insight Wealth Strategies LLC’s holdings in Zoetis were worth $1,764,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in ZTS. Glassman Wealth Services boosted its holdings in shares of Zoetis by 306.5% during the first quarter. Glassman Wealth Services now owns 252 shares of the company’s stock worth $25,000 after purchasing an additional 190 shares during the period. JJJ Advisors Inc. acquired a new stake in shares of Zoetis during the second quarter worth approximately $25,000. Private Ocean LLC acquired a new stake in shares of Zoetis during the first quarter worth approximately $27,000. Altshuler Shaham Ltd boosted its holdings in shares of Zoetis by 198.8% during the second quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock worth $29,000 after purchasing an additional 169 shares during the period. Finally, Next Capital Management LLC boosted its holdings in shares of Zoetis by 156.5% during the second quarter. Next Capital Management LLC now owns 295 shares of the company’s stock worth $33,000 after purchasing an additional 180 shares during the period. Institutional investors own 90.42% of the company’s stock.
Several research firms recently commented on ZTS. Craig Hallum raised their price target on shares of Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. SunTrust Banks raised their price target on shares of Zoetis from $120.00 to $130.00 and gave the stock a “hold” rating in a report on Tuesday, August 13th. Barclays raised their price target on shares of Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. BMO Capital Markets raised their price target on shares of Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a report on Thursday, May 9th. Finally, Guggenheim began coverage on shares of Zoetis in a report on Thursday, May 23rd. They set a “buy” rating and a $114.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $115.13.
ZTS traded down $2.35 during midday trading on Friday, hitting $124.29. 790,090 shares of the company’s stock traded hands, compared to its average volume of 1,927,368. The company has a market cap of $60.20 billion, a PE ratio of 39.71, a price-to-earnings-growth ratio of 3.18 and a beta of 0.92. The stock’s fifty day simple moving average is $118.06 and its 200-day simple moving average is $105.25. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. Zoetis Inc has a one year low of $78.90 and a one year high of $128.41.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 earnings per share. On average, research analysts expect that Zoetis Inc will post 3.57 EPS for the current year.
In related news, Director Willie M. Reed sold 1,900 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $110.58, for a total transaction of $210,102.00. Following the transaction, the director now owns 2,816 shares of the company’s stock, valued at $311,393.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $109.79, for a total transaction of $672,244.17. Following the transaction, the executive vice president now directly owns 49,369 shares in the company, valued at approximately $5,420,222.51. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,432 shares of company stock worth $5,083,246. Insiders own 0.29% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: Hold Rating
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.